Abstract
Mastocytosis is a clonal disease derived from hematopoietic bone marrow progenitor cells. Clinical manifestations of the disease vary greatly depending on tissue involvement. Omalizumab is a recombinant humanized monoclonal anti-IgE antibody licensed in the treatment of asthma with increasing reports of clinical eficiency in other allergic diseases. We describe a case of a patient with mastocytosis responsive clinically and patho-physiologically after anti-IgE treatment.
MeSH terms
-
Adult
-
Anaphylaxis / drug therapy*
-
Anaphylaxis / immunology
-
Anti-Allergic Agents / therapeutic use*
-
Antibodies, Anti-Idiotypic / therapeutic use*
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Humans
-
Male
-
Mast Cells / drug effects*
-
Mast Cells / immunology
-
Mastocytosis / drug therapy*
-
Mastocytosis / immunology
-
Omalizumab
-
Skin / drug effects*
-
Skin / immunology
-
Treatment Outcome
Substances
-
Anti-Allergic Agents
-
Antibodies, Anti-Idiotypic
-
Antibodies, Monoclonal, Humanized
-
anti-IgE antibodies
-
Omalizumab